← Back to Clinical Trials
Recruiting Phase 2 NCT04673643

Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Dry Eye Disease
Sponsor Beijing Tongren Hospital
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 128
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2021-07-01
Completion 2024-10-01
Interventions
Transcutaneous Auricular Vagus Nerve StimulationHyaluronic acid eye drops

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Objective: To evaluate the effect of transcutaneous auricular vagus nerve stimulation (taVNS) for the patients with dry eye disease with meibomian gland dysfunction. Methods: We enrolled 256 patients at Beijing Tongren Hospital. Patients completed questionnaires at baseline, 1 month, 3 months, and 6 months.OSDI score, TBUT, Schirmer I, tCFS, MGD score, and psychological status to evaluate the therapeutic effects. A difference of P \< 0.05 was considered statistically significant.

Eligibility Criteria

Inclusion Criteria: 1. Age \>=18 and Age \<=75. 2. Clinical diagnosis of dry eye disease. Exclusion Criteria: 1. History of depression, tumors, thyroid disease, diabetes, cardiac diseases. 2. History of phthalmology surgery. 3. Pregnant or lactating women.

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE DRY EYE DISEASE TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}